Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

Summary

To investigate the efficacy and safety of hirudin plus aspirin therapy compared with warfarin in the secondary prevention of cardioembolic stroke due to nonvalvular atrial fibrillation.

Conditions

• Cardioembolic Stroke
• Atrial Fibrillation

Interventions

DRUG

hirudin plus aspirin

natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily

DRUG

Warfarin

an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.

Sponsors & Collaborators

• Xi'an Central Hospital

  collaborator OTHER

• Shaanxi people's Hospital

  collaborator UNKNOWN

• The Third Hospital of PLA

  collaborator UNKNOWN

• Hanzhong Central Hospital

  collaborator OTHER

• Xianyang 215 hospital

  collaborator UNKNOWN

• Yulin Second Hospital

  collaborator UNKNOWN

• Yan'an University Affiliated Hospital

  collaborator OTHER

• Baoji Central Hospital

  collaborator OTHER

• Ankang Central Hospital

  collaborator OTHER

• Baoji People's Hospital

  collaborator UNKNOWN

• Yan'an people's Hospital

  collaborator UNKNOWN

• 451 Hospital

  collaborator UNKNOWN

• Shangluo Central Hospital

  collaborator OTHER

• Central Hospital of China Railway 20th Bureau

  collaborator UNKNOWN

• Xiangyang Central Hospital

  collaborator OTHER

• Xi'an Ninth Hospital

  collaborator UNKNOWN

• Shangluo Second People's Hospital

  collaborator UNKNOWN

• Xijing Hospital

  lead OTHER

Principal Investigators

• wen jiang, MD,PhD · The Department of Neurology , Xijing Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-06-30

Primary Completion

2016-12-31

Completion

2018-10-31

Countries

• China

Study Locations